TCGA-BH-A202-01A-11R-A14M-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 26
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.530
- E2F_TARGETS+0.520
- PROTEIN_SECRETION+0.470
- G2M_CHECKPOINT+0.440
- MYC_TARGETS_V1+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ALLOGRAFT_REJECTION+0.370
- ANDROGEN_RESPONSE+0.340
- INTERFERON_GAMMA_RESPONSE+0.340
- GLYCOLYSIS+0.300
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.290
- NOTCH_SIGNALING-0.260
- MYOGENESIS-0.230
- APICAL_JUNCTION-0.180
- KRAS_SIGNALING_DN-0.180
- P53_PATHWAY-0.180
- TGF_BETA_SIGNALING-0.180
- TNFA_SIGNALING_VIA_NFKB-0.140
- APICAL_SURFACE-0.070
- HEDGEHOG_SIGNALING-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797278 | — | cohortSC | 0.844 |
| 2 | TCGA-A8-A094-01A-11R-A00Z-07 | — | C | 0.841 |
| 3 | TCGA-C8-A278-01A-11R-A169-07 | — | C | 0.839 |
| 4 | faffc96a-760c-405c-9bec-d2ec116b4a1d | — | — | 0.839 |
| 5 | TCGA-18-4721-01A-01R-1443-07 | — | cohortSQ2 | 0.832 |
| 6 | 930630ee-1c36-4567-aeff-042eef1654e6 | — | — | 0.831 |
| 7 | BS_2EN3X6HB | high-grade glioma | — | 0.827 |
| 8 | SJEPD030367_D2.RNA-Seq | EPN | Supratentorial EPN | 0.816 |
| 9 | DRR168585 | — | — | 0.813 |
| 10 | f9c74189-6bdc-49b9-b984-917ffe2b097d | — | — | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.530 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |